PT  - JOURNAL ARTICLE
AU  - Ebstein, Frédéric
AU  - Küry, Sébastien
AU  - Most, Victoria
AU  - Rosenfelt, Cory
AU  - Boyer, Marie-Pier Scott-
AU  - van Woerden, Geeske M.
AU  - Besnard, Thomas
AU  - Papendorf, Jonas Johannes
AU  - Studencka-Turski, Maja
AU  - Wang, Tianyun
AU  - Hsieh, Tzung-Chien
AU  - Golnik, Richard
AU  - Baldridge, Dustin
AU  - Forster, Cara
AU  - de Konink, Charlotte
AU  - Teurlings, Selina M.W.
AU  - Vignard, Virginie
AU  - van Jaarsveld, Richard H.
AU  - Ades, Lesley
AU  - Cogné, Benjamin
AU  - Mignot, Cyril
AU  - Deb, Wallid
AU  - Jongmans, Marjolijn C.J.
AU  - Sessions Cole, F.
AU  - van den Boogaard, Marie-José H.
AU  - Wambach, Jennifer A.
AU  - Wegner, Daniel J.
AU  - Yang, Sandra
AU  - Hannig, Vickie
AU  - Brault, Jennifer Ann
AU  - Zadeh, Neda
AU  - Bennetts, Bruce
AU  - Keren, Boris
AU  - Gélineau, Anne-Claire
AU  - Powis, Zöe
AU  - Towne, Meghan
AU  - Bachman, Kristine
AU  - Seeley, Andrea
AU  - Beck, Anita E.
AU  - Morrison, Jennifer
AU  - Westman, Rachel
AU  - Averill, Kelly
AU  - Brunet, Theresa
AU  - Haasters, Judith
AU  - Carter, Melissa T.
AU  - Osmond, Matthew
AU  - Wheeler, Patricia G.
AU  - Forzano, Francesca
AU  - Mohammed, Shehla
AU  - Trakadis, Yannis
AU  - Accogli, Andrea
AU  - Harrison, Rachel
AU - Deciphering Developmental Disorders Study
AU - Care4Rare Canada Consortium
AU  - Rondeau, Sophie
AU  - Baujat, Geneviève
AU  - Barcia, Giulia
AU  - Feichtinger, René Günther
AU  - Mayr, Johannes Adalbert
AU  - Preisel, Martin
AU  - Laumonnier, Frédéric
AU  - Knaus, Alexej
AU  - Isidor, Bertrand
AU  - Krawitz, Peter
AU  - Völker, Uwe
AU  - Hammer, Elke
AU  - Droit, Arnaud
AU  - Eichler, Evan E.
AU  - Elgersma, Ype
AU  - Hildebrand, Peter W.
AU  - Bolduc, François
AU  - Krüger, Elke
AU  - Bézieau, Stéphane
TI  - De novo variants in the <em>PSMC3</em> proteasome AAA-ATPase subunit gene cause neurodevelopmental disorders associated with type I interferonopathies
AID  - 10.1101/2021.12.07.21266342
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.07.21266342
4099  - http://medrxiv.org/content/early/2021/12/07/2021.12.07.21266342.short
4100  - http://medrxiv.org/content/early/2021/12/07/2021.12.07.21266342.full
AB  - A critical step in preserving protein homeostasis by the ubiquitin-proteasome system (UPS) is the recognition, binding, unfolding, and translocation of protein substrates by AAA-ATPase proteasome subunits for degradation by 26S proteasomes. Here, we identified fourteen different de novo missense variants in the PSMC3 gene encoding the AAA-ATPase proteasome subunit Rpt5 in twenty-two unrelated heterozygous subjects with an autosomal dominant form of neurodevelopmental delay and intellectual disability. Indeed, depletion of PSMC3 impaired reversal learning capabilities in a Drosophila model. The PSMC3 variants cause proteasome dysfunction in patient-derived cells by disruption of substrate translocation, proteotoxic stress and proteostatic imbalances, as well as alterations in proteins controlling developmental and innate immune programs. Molecular analysis confirmed the induction of cellular stress responses and dysregulated mitophagy along with an elevated type I interferon (IFN) signature. Our data define PSMC3 variants as the genetic cause of proteotoxic stress alerting the innate immune system to mount a type I IFN response and link neurodevelopmental syndromes to interferonopathies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the German Research Foundation (SFBTR167, RGT2719-PRO project B4) to EK, E-Rare project GENOMIT (Austrian Science Fund FWF, I4695-B) to JAM, in part, by US National Institutes of Health (NIH) grants (R01MH101221) and a grant from the Simons Foundation (SFARI #608045) to E.E.E.; E.E.E. is an investigator of the Howard Hughes Medical Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the CHU de Nantes ethics committee (Medical Genetic Research Programme number DC-2011-1399).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors